Document:

Exhibit
10.6

 

COMMON
SHARE PURCHASE WARRANT

 

	Warrant
    Shares: 500,000	Issuance
    Date: August 30, 2021

 

THIS
COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, MCUS LLC or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the three year
anniversary hereof_(the “Termination Date”) but not thereafter, to subscribe for and purchase from Stemtech Corporation
(“Stemtech”), up to 500,0000 Common Shares (as subject to adjustment hereunder, the “Warrant Shares”),
exercisable at a strike price or exercise price of $3.00 and expiring in 3 years from August 30, 2021.

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings as set forth in that certain Note
Purchase Agreement (the “Purchase Agreement”). In addition to the terms defined elsewhere in this Warrant, the following
terms have the meanings indicated in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares
are then listed or quoted on a Trading Market, the bid price of the Common Shares for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of an Common Share as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to Stemtech, the fees and expenses of which shall be paid by Stemtech.

 

“Board
of Directors” means the board of directors of Stemtech.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

    	 

    	 

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Excluded
Securities” means (a) Common Shares issued or deemed to have been issued by Stemtech pursuant to an equity incentive plan that
has been approved by the Board of Directors pursuant to which Stemtech’s securities may be issued to any employee, consultant,
officer or director for services provided to Stemtech, (b) the Common Shares issued or deemed to be issued by Stemtech upon conversion
or exercise of any Common Share Equivalents outstanding prior to the Initial Exercise Date, and (c) Common Shares and Common Share Equivalents
issued or deemed to have been issued by Stemtech pursuant to resolutions of the Board of Directors (including its Compensation Committee)
adopted prior to the Initial Exercise Date.

 

“Common
Shares” means the Common shares of Stemtech, and any other class of securities into which such securities may hereafter be
reclassified or changed.

 

“Common
Share Equivalents” means any securities of Stemtech or its subsidiaries which would entitle the holder thereof to acquire at
any time Common Shares, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Registration
Statement” means Stemtech’s registration statement on Form S-1 Within 180 days from the execution of this document.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the Common Shares are traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York
Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

“Transfer
Agent” means Empire Stock, the current transfer agent of Stemtech, with a mailing address of 1859 Whitney Mesa Dr., Henderson,
NV 89014 and a telephone number of 702-818-5898, and any successor transfer agent of Stemtech.

 

    	 

    	 

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Shares for such date (or the nearest preceding date)
on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Shares so reported, or (d) in all other cases, the fair market value of one Common
Share as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then
outstanding and reasonably acceptable to Stemtech, the fees and expenses of which shall be paid by Stemtech.

 

“Warrant
Agent” means the Transfer Agent and any successor warrant agent of Stemtech.

 

“Warrants”
means this Warrant and other Common Share purchase warrants of this series issued by Stemtech pursuant to the Registration Statement.

 

Section
2. Exercise.

 

(a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to Stemtech of a duly executed facsimile
copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Notice
of Exercise will be effective on the day given up to 11:59 pm. Within the earlier of (i) two (2) Trading Days and (ii) the number of
Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire
transfer or cashier’s check drawn on a United States bank unless the cashlessCash exercise procedure specified in Section 2(c)
below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to Stemtech until the Holder has purchased all of the
Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to Stemtech for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to Stemtech.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and Stemtech shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. Stemtech shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.

 

    	 

    	 

    

 

Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing
this Warrant held in book-entry form through the Depository Trust Company (“DTC”) (or another established clearing corporation
performing similar functions) shall effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing
corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are
required by DTC (or such other clearing corporation, as applicable).

 

(b)
Exercise Price. The exercise price per Common Share under this Warrant shall be at $3.00 per share (the “Exercise Price”
or “Strike Price”).

 

(c)
CashlessCash Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in
whole or in part, by tendering of the same amount, to wit $3.00 per share. Otherwise, by March, 2022 may be utilized under Rule 144.

 

If
Warrant Shares are issued in such a cashlessCash exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. Stemtech agrees
not to take any position contrary to this Section 2(c).

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashlessCash exercise pursuant
to this Section 2(c).

 

(d)
Mechanics of Exercise.

 

(i)
Delivery of Warrant Shares Upon Exercise. Stemtech shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if Stemtech is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashlessCash exercise, and otherwise by physical delivery of
a certificate, registered in Stemtech’s share register in the name of the Holder or its designee, for the number of Warrant Shares
to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date
that is the earliest of (i) two (2) Trading Days after the delivery to Stemtech of the Notice of Exercise, (ii) one (1) Trading Day after
delivery of the aggregate Exercise Price to Stemtech and (iii) the number of Trading Days comprising the Standard Settlement Period after
the delivery to Stemtech of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two
(2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.
If Stemtech fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, Stemtech shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Shares on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. Stemtech agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on Stemtech’s primary
Trading Market with respect to the Common Shares as in effect on the date of delivery of the Notice of Exercise, but in no event earlier
than one (1) Trading Day after each Exercise Date.

 

    	 

    	 

    

 

(ii)
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, Stemtech shall, at the request of a
Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.

 

(iii)
Rescission Rights. If Stemtech fails to transmit or fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

(iv)
Compensation for Buy-In on Failure to Timely Deliver Warrant Upon Exercise. In addition to any other rights available to the Holder,
if Stemtech fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Common
Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a “Buy-In”), then Stemtech shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the Common Shares so purchased exceeds (y) the amount obtained by
multiplying (1) the Warrant Shares that Stemtech was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of Common Shares that would have been issued had Stemtech
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Shares having a total
purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Common Shares with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence Stemtech shall be required to pay
the Holder $1,000. The Holder shall provide Stemtech written notice indicating the amounts payable to the Holder in respect of the Buy-In
and, upon request of Stemtech, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief with respect to Stemtech’s failure to timely deliver Common Shares upon exercise of the Warrant as required pursuant to
the terms hereof.

 

    	 

    	 

    

 

(v)
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, Stemtech
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

(vi)
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares all of which taxes and expenses shall be paid by Stemtech,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and Stemtech may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. Stemtech shall
pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or
another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

(vii)
Closing of Books. Stemtech will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

(viii)
Call Provision. Subject to the provisions of Section 2(f), at any time following the ninety (90) day anniversary of Initial Exercise
Date, Stemtech may call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet been delivered
(such right, a “Call”) for consideration in cash equal to 8% of the aggregate Exercise Price of the Warrants subject
to the Call (such amount, the “Call Consideration Amount”). To exercise this right, Stemtech must deliver to the Holder
an irrevocable written notice (a “Call Notice”), indicating therein the portion of unexercised portion of this Warrant
to which such notice applies, and delivery of the Call Consideration Amount in cash to the Holder within one (1) Trading Day following
delivery of Call Notice (such date, the “Payment Date”). If such payment is made, then any portion of this Warrant
subject to such Call Notice for which a Notice of Exercise shall not have been received by the Call Date will be cancelled at 6:30 p.m.
(New York City time) on the thirtieth (30) day following the Payment Date (such date and time, the “Call Date”). Any
unexercised portion of this Warrant to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance
thereof, Stemtech covenants and agrees that Stemtech shall honor all Notices of Exercise with respect to Warrant Shares subject to a
Call Notice that are tendered through 6:30 p.m. (New York City time) on the Call Date. The parties agree that any Notice of Exercise
delivered following a Call Notice which calls less than all of the Warrants shall first reduce to zero the number of Warrant Shares subject
to such Call Notice prior to reducing the remaining Warrant Shares available for purchase under this Warrant. For example, if (A) this
Warrant then permits the Holder to acquire 100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant Shares, and (C) prior to 6:30
p.m. (New York City time) on the Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x) on the Call
Date the right under this Warrant to acquire 25 Warrant Shares will be automatically cancelled, (y) Stemtech, in the time and manner
required under this Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the exercises following receipt
of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to adjustment
as herein provided and subject to subsequent Call Notices). Subject again to the provisions of this Section 2(f), Stemtech may deliver
subsequent Call Notices for any portion of this Warrant for which the Holder shall not have delivered a Notice of Exercise.

 

    	 

    	 

    

 

(e)
Holder’s Exercise Limitations. Stemtech shall not effect any exercise of this Warrant, and a Holder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of Common Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Common
Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
Common Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion
of any other securities of Stemtech (including, without limitation, any other Common Share Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that Stemtech is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be
in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and Stemtech
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding Common Shares, a Holder may rely on the
number of outstanding Common Shares as reflected in (A) Stemtech’s most recent periodic or annual report filed with the Commission,
as the case may be, (B) a more recent public announcement by Stemtech or (C) a more recent written notice by Stemtech or the Transfer
Agent setting forth the number of Common Shares outstanding. Upon the written or oral request of a Holder, Stemtech shall within one
Trading Day confirm orally and in writing to the Holder the number of Common Shares then outstanding. In any case, the number of outstanding
Common Shares shall be determined after giving effect to the conversion or exercise of securities of Stemtech, including this Warrant,
by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Common Shares was reported.
The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder, 9.99%) of the number of Common
Shares outstanding immediately after giving effect to the issuance of Common Shares issuable upon exercise of this Warrant. The Holder,
upon notice to Stemtech, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Common Shares outstanding immediately after giving
effect to the issuance of Common Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after
such notice is delivered to Stemtech. The provisions of this paragraph shall be construed and implemented in a manner otherwise than
in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    	 

    	 

    

 

Section
3. Certain Adjustments.

 

(a)
Stock Dividends and Splits. If Stemtech, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Shares or any other equity or equity equivalent securities payable in Common
Shares (which, for avoidance of doubt, shall not include any Common Shares issued by Stemtech upon exercise of this Warrant), (ii) subdivides
outstanding Common Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Common
Shares into a smaller number of shares, or (iv) issues by reclassification of Common Shares any shares of capital stock of Stemtech,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Common Shares
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification; provided
that if Stemtech effectuates a reverse split of its Common Stock for a ratio in excess of 20:1, the resulting adjusted Warrant Shares
and Exercise Price shall be limited to a 20:1 ratio

 

(b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time Stemtech grants,
issues or sells any Common Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of Common Shares (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined
for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Common Shares as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

(c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if Stemtech shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of Common Shares acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of Common Shares are to be determined for the participation in such Distribution (provided, however,
to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any Common Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).

 

    	 

    	 

    

 

(d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) Stemtech, directly or indirectly, in one or more
related transactions effects any merger or consolidation of Stemtech with or into another Person, (ii) Stemtech, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by Stemtech
or another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their shares for
other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Shares, (iv) Stemtech,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities,
cash or property, or (v) Stemtech, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Shares (not
including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Common Shares of the successor or acquiring
corporation or of Stemtech, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share in such Fundamental Transaction,
and Stemtech shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, Stemtech or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such
Fundamental Transaction; provided, however, if the Fundamental Transaction is not within Stemtech’s
control, including not approved by Stemtech’s Board of Directors, the Holder shall only be entitled to receive from Stemtech or
any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in
the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders
of Common Shares of Stemtech in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Shares are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the
Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day
volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last
VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment of the Black Scholes
Value will be made by wire transfer of immediately available funds within five Business Days of the Holder’s election (or, if later,
on the effective date of the Fundamental Transaction). Stemtech shall cause any successor entity in a Fundamental Transaction in which
Stemtech is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of Stemtech under
this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Common
Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant referring to “Stemtech” shall refer instead to the Successor Entity),
and may exercise every right and power of Stemtech and shall assume all of the obligations of Stemtech under this Warrant with the same
effect as if such Successor Entity had been named as Stemtech herein.

 

    	 

    	 

    

 

(e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of Common Shares deemed to be issued and outstanding as of a given
date shall be the sum of the number of Common Shares (excluding treasury shares, if any) issued and outstanding.

 

(f)
Notice to Holder.

 

(i)
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, Stemtech
shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

(ii)
Notice to Allow Exercise by Holder. If (A) Stemtech shall declare a dividend (or any other distribution in whatever form) on the
Common Shares, (B) Stemtech shall declare a special nonrecurring cash dividend on or a redemption of the Common Shares, (C) Stemtech
shall authorize the granting to all holders of the Common Shares rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of Stemtech shall be required in connection with any reclassification
of the Common Shares, any consolidation or merger to which Stemtech is a party, any sale or transfer of all or substantially all of the
assets of Stemtech, or any compulsory share exchange whereby the Common Shares are converted into other securities, cash or property,
or (E) Stemtech shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of Stemtech, then,
in each case, Stemtech shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address
as it shall appear upon the Warrant Register of Stemtech, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Shares of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Shares of record shall be entitled to exchange their Common Shares for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver
such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding
Stemtech or any of its subsidiaries, Stemtech shall simultaneously file such notice with the Commission pursuant to a Report of Foreign
Private Issuer on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    	 

    	 

    

 

Section
4. Adjustment of Exercise Price. The Exercise Price shall be adjusted from time to time as follows:

 

(a)
If and whenever on or after the Initial Exercise Date Stemtech issues or sells, or is deemed to have issued or sold, any Common Shares,
other than Excluded Securities, for a consideration per Common Share (the “New Issuance Price”) less than the Exercise
Price per Common Share in effect immediately prior to such issuance or sale (the “Applicable Price”), then immediately
after such issue or sale the Exercise Price then in effect shall be reduced to an amount equal to such New Issuance Price.

 

(b)
Effect on Exercise Price of Certain Events. For purposes of determining the adjusted Exercise Price under Section 4(a) above,
the following shall be applicable:

 

(i)
Issuance of Options. If after the date hereof, Stemtech in any manner grants any options to purchase Common Shares other than
Excluded Securities (“Options”) and the lowest price per Common Share for which one Common Share is issuable upon
the exercise of any such Option or upon conversion or exchange of any convertible securities issuable upon exercise of any such Option
is less than the Applicable Price, then such Common Share shall be deemed to be outstanding and to have been issued and sold by Stemtech
at the time of the granting or sale of such Option for such price per share. For purposes of this Section 4(b)(i), the lowest
price per share for which one Common Share is issuable upon exercise of such Options or upon conversion or exchange of such convertible
securities shall be equal to the sum of the lowest amounts of consideration (if any) received or receivable by Stemtech with respect
to any one Common Share (x) upon the granting or sale of the Option and (y) upon exercise of the Option or upon conversion or exchange
of any convertible security issuable upon exercise of such Option. No further adjustment of the Exercise Price shall be made upon the
actual issuance of such Common Shares or of such convertible securities upon the exercise of such Options or upon the actual issuance
of such Common Shares upon conversion or exchange of such convertible securities.

 

    	 

    	 

    

 

(ii)
Change in Option Price or Rate of Conversion. in any Options, the additional consideration, if any, payable upon the issue, conversion
or exchange of any convertible securities, or the rate at which any convertible securities are convertible into or exchangeable for Common
Shares changes at any time (in each case excluding Excluded Securities), the Exercise Price in effect at the time of such change shall
be adjusted to the Exercise Price that would have been in effect at such time had such Options or convertible securities provided for
such changed purchase price, additional consideration or changed conversion rate, as the case may be, at the time initially granted,
issued or sold. For purposes of this Section 4(b)(ii), if the terms of any Option or convertible security that was outstanding
as of the Initial Exercise Date of this Warrant are changed in the manner described in the immediately preceding sentence, then such
Option or convertible security and the Common Shares deemed issuable upon exercise, conversion or exchange thereof shall be deemed to
have been issued as of the date of such change. No adjustment pursuant to this Section 4(b) shall be made if such adjustment would
result in an increase of the Exercise Price then in effect.

 

(iii)
Calculation of Consideration Received. If any Common Shares, Options or convertible securities are issued or sold or deemed to
have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount received by Stemtech therefor.
If any Common Shares, Options or convertible securities are issued or sold for a consideration other than cash, the amount of such consideration
received by Stemtech will be the fair value of such consideration, except where such consideration consists of marketable securities,
in which case the amount of consideration received by Stemtech will be the market price of such securities on the date of receipt of
such securities. If any Common Shares, Options or convertible securities are issued to the owners of the non-surviving entity in connection
with any merger in which Stemtech is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of
such portion of the net assets and business of the non-surviving entity as is attributable to such Common Shares, Options or convertible
securities, as the case may be. The fair value of any consideration other than cash or securities will be determined jointly by Stemtech
and the holders of Warrants representing at least two-thirds of the Warrant Shares issuable upon exercise of the Warrants then outstanding.
If such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the “Valuation
Event”), the fair value of such consideration will be determined within five (5) Business Days after the tenth (10th) day following
the Valuation Event by an independent, reputable appraiser jointly selected by Stemtech and the holders of Warrants representing at least
two-thirds of the Warrant Shares issuable upon exercise of the Warrants then outstanding. The determination of such appraiser shall be
final and binding upon all parties and the fees and expenses of such appraiser shall be borne jointly by Stemtech and the holders of
Warrants.

 

    	 

    	 

    

 

(iv)
Integrated Transactions. In case any Option is issued in connection with the issue or sale of other securities of Stemtech, together
comprising one integrated transaction in which no specific consideration is allocated to such Options by the parties thereto, then for
purposes of determining the consideration received by Stemtech upon the granting of each Option, the Options will be deemed to have been
issued for a consideration of $.01 per Option.

 

(v)
Treasury Shares. The number of Common Shares outstanding at any given time does not include shares owned or held by or for the
account of Stemtech, and the disposition of any shares so owned or held will be considered an issue or sale of Common Shares.

 

(vi)
Record Date. If Stemtech takes a record of the holders of Common Shares for the purpose of entitling them (x) to receive a dividend
or other distribution payable in Common Shares, Options or in convertible securities or (y) to subscribe for or purchase Common Shares,
Options or convertible securities, then such record date will be deemed to be the date of the issue or sale of the Common Shares deemed
to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting
of such right of subscription or purchase, as the case may be.

 

(c)
Notice to Holder. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 4, Stemtech shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

Section
5. Transfer of Warrant.

 

(a)
Transferability. Upon Notice to the Company, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of Stemtech or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, Stemtech shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and
in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to Stemtech unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to Stemtech within three (3) Trading Days of the date on which the Holder delivers
an assignment form to Stemtech assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	 

    	 

    

 

(b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
Stemtech, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the
Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, Stemtech shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or
combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this
Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

(c)
Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. Stemtech and the Warrant Agent
may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
6. Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of Stemtech prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section
3.

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. Stemtech covenants that upon receipt by Stemtech of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, Stemtech will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

(c)
Saturdays, Sundays, Jewish & Federal Holidays, etc. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a non-holiday Business Day, then, such action may be taken or such right may be
exercised on the next succeeding Business Day.

 

(d)
Authorized Shares.

 

Stemtech
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Shares a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. Stemtech
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. Stemtech will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Shares may be listed. Stemtech covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by Stemtech in respect of the issue thereof (other than taxes in
respect of any transfer occurring contemporaneously with such issue).

 

    	 

    	 

    

 

Except
and to the extent as waived or consented to by the Holder, Stemtech shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, Stemtech will (i) take all such action as may be necessary or appropriate in order that Stemtech may validly and legally issue
fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (ii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to
enable Stemtech to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, Stemtech shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof.

 

(e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Stemtech agrees that it hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein that is brought against a party hereto (or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents), and Stemtech hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not subject to the jurisdiction of any such court, that such suit, action or proceeding is
improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding
to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party
for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

    	 

    	 

    

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize Cash exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

(g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant, if Stemtech willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, Stemtech shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

(h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service,addressed to Stemtech, at 10370 USA Today Way, Miramar, Fla 33025 or such other address as Stemtech may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by Stemtech hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of Stemtech. Any notice or other
communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice
or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section prior
to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding Stemtech
or any subsidiaries, Stemtech shall simultaneously file such notice with the Commission Form 8-K.

 

(i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Shares or as a stockholder of Stemtech, whether such liability is asserted by Stemtech
or by creditors of Stemtech.

 

(j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. Stemtech agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the
defense in any action for specific performance that a remedy at law would be adequate.

 

    	 

    	 

    

 

(k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of Stemtech and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.

 

(l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of Stemtech, on the
one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.

 

(m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

(n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

(o)
Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued
subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant
Agency Agreement, the provisions of this Warrant shall govern and be controlling.

 

(p)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by Stemtech shall
be delivered in accordance with the notice provisions of the Purchase Agreement.

 

[Signature
page follows.]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, Stemtech has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

STEMTECH
CORPORATION

 

_________________________________

David
E. Price, Esq. Secretary, Corp Counsel

with
specific instructions and Authority of Charles Arnold, Dir., CEO

 

[Signature
Page to Warrant]

 

    	 

    	 

    

 

NOTICE
OF EXERCISE

 

To:
Stemtech Corporation.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of Stemtech pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

☐
in lawful money of the United States; or

 

☐
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the Cash exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

_______________________________

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: _______________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

 

Name
of Authorized Signatory: ___________________________________________________________________

 

Title
of Authorized Signatory: ____________________________________________________________________

 

Date:
_______________________________________________________________________________________

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 	 
	 	 	(Please
    Print)
	 	 	 
	Address:	 	 
	 	 	(Please
    Print)
	 	 	 
	Phone
    Number:	 	 
	Email
    Address:	 	 
	Dated:
    _____________ __, ______	 	 
	Holder’s
    Signature:________________________	 	 
	Holder’s
    Address:Exhibit
10.7

 

REGISTRATION
RIGHTS AGREEMENT

 

THIS
REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of August 30, 2021 (the “Closing Date”),
by and among Stemtech Corporation (the “Company”), and the Lender identified on the signature pages hereto (including
its successors and assigns, each a “Lender” ).

 

RECITALS

 

WHEREAS,
the Company and the Lender are parties to the Securities Purchase Agreement (the “Purchase Agreement”), dated as of
the date hereof, as such may be amended and supplemented from time to time;

 

WHEREAS,
the Company and the Lender are parties to a Warrant (the “Warrant”) of even date herewith for the purchase of 500,000
shares of Common Stock;

 

WHEREAS,
the Lender’s obligations under the Purchase Agreement are conditioned upon certain registration rights under the Securities Act
of 1933, as amended (the “Securities Act”); and

 

WHEREAS,
the Lender and the Company desire to provide for the rights of registration under the Securities Act as are provided herein upon the
execution and delivery of this Agreement by the Lender and the Company.

 

NOW,
THEREFORE, in consideration of the promises, covenants and conditions set forth herein, the parties hereto hereby agree as follows:

 

1.
Registration Rights.

 

1.1
Definitions. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement.
As used in this Agreement, the following terms shall have the meanings set forth below:

 

	 	(a)	“Business
                                            Day” means any day except Saturday, Sunday and any day which shall be a legal holiday
                                            or a day on which banking institutions in the State of New York generally are authorized
                                            or required by law or other government actions to close.

    

	 	 	 
	 	(b)	“Commission”
                                            means the United States Securities and Exchange Commission.

    

 

	 	(c)	“Common
    Stock” means the Company’s Common Shares.

 

    	 

    	 

    

 

	 	(d)	Omitted.
	 	 	 
	 	(e)	“Exchange
    Act” means the Securities Exchange Act of 1934, as amended.
	 	 	 
	 	(f)	“Filing
    Date” means 180 days after the Closing Date.
	 	 	 
	 	(g)	“Holder”
    or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.
	 	 	 
	 	(h)	“Lender”
    means any person owning Registrable Securities who becomes party to this Agreement by executing a counterpart signature page hereto,
    which is accepted by the Company.
	 	 	 
	 	(i)	The
    terms “register,” “registered” and “registration” refer to a registration
    effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration
    or ordering of effectiveness of such registration statement or document.
	 	 	 
	 	(j)	“Registrable
    Securities” means 100% of the maximum number of the Shares issuable upon conversion of the Notes and exercise of the Warrants
    issued pursuant to the Purchase Agreement as of the Trading Day; provided, however, that Registrable Securities shall
    not include any securities of the Company that have previously been registered and remain subject to a currently effective registration
    statement or which have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold
    in a private transaction in which the transferor’s rights under this Section 1 are not assigned.
	 	 	 
	 	(k)	“Rule
    144” means Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to
    time, or any similar successor rule that may be promulgated by the Commission.
	 	 	 
	 	(l)	“Rule
    415” means Rule 415 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to
    time, or any similar successor rule that may be promulgated by the Commission.
	 	 	 
	 	(m)	“Shares”
    means the Company’s Common Shares.

 

    	 

    	 

    

 

	 	1.2	Company
    Registration.

 

(a)
On or prior to the Filing Date, the Company shall prepare and file with the Commission a registration statement covering the Registrable
Securities for an offering to be made on a continuous basis pursuant to Rule 415. The registration statement shall be on Form S-1 or,
if the Company is so eligible, on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities
on Form S-1 or Form S-3, as the case may be, in which case such registration shall be on another appropriate form in accordance herewith)
and shall contain (unless otherwise directed by Lender) substantially the “Plan of Distribution” attached hereto as
Annex A. The Company shall cause the registration statement to become effective and remain effective as provided herein. The Company
shall use its reasonable best efforts to cause the registration statement to be declared effective under the Securities Act as soon as
possible. The Company shall use its best efforts to keep the registration statement continuously effective under the Securities Act until
all Registrable Securities covered by such registration statement have been sold, or may be sold without the requirement to be in compliance
with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, as determined by the counsel to the Company
(the “Effectiveness Period”).

 

(b)
The Company shall prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement
as may be necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness
Period and prepare and file with the Commission such additional Registration Statements as necessary in order to register for resale
under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or supplemented by any required
Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424 (or any similar provisions then in force) promulgated
under the Securities Act; (iii) respond as promptly as possible, but in no event later than twenty (20) Business Days, to any comments
received from the Commission with respect to the Registration Statement or any amendment thereto and as promptly as possible provide
the Holders true and complete copies of all correspondence from and to the Commission relating to the Registration Statement; (iv) file
the final prospectus pursuant to Rule 424 of the Securities Act no later than two (2) Business Days following the date the Registration
Statement is declared effective by the Commission; and (v) comply in all material respects with the provisions of the Securities Act
and the Exchange Act with respect to the disposition of all Registrable Securities covered by the Registration Statement during the Effectiveness
Period in accordance with the intended methods of disposition by the Holders thereof set forth in the Registration Statement as so amended
or in such Prospectus as so supplemented. The Company shall declare the Registration Statement Effective within 60 days from the Filing
Date.

 

(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock
then registered in a registration statement, the Company shall file as soon as reasonably practicable an additional registration statement
covering the resale of not less than the number of such Registrable Securities.

 

(d)
The Company shall bear and pay all costs and expenses incurred in connection with any registration, filing or qualification of Registrable
Securities with respect to the registrations pursuant to this Section 1.2 for the Lender, including (without limitation) all registration,
filing and qualification fees, printer’s fees, accounting fees and fees and disbursements of counsel for the Company, but excluding
any brokerage or underwriting fees, discounts and commissions relating to Registrable The Company covenants it will provide the proposed
Registration Statement to Lender and its counsel at least two (2) business days before filing for their review and comment. The Company
agrees it will accept all such reasonable comments and proposed changes unless such comments and changes would reasonably be expected
to result in a violation of applicable securities laws.

 

    	 

    	 

    

 

(e)
If at any time during the Effectiveness Period there is not an effective Registration Statement covering all of the Registrable Securities,
then the Company shall notify the Lender in writing at least fifteen (15) days prior to the filing of any registration statement under
the Securities Act, in connection with a public offering of shares of Common Stock (including, but not limited to, registration statements
relating to secondary offerings of securities of the Company but excluding any registration statements (i) on Form S-4 or S-8 (or any
successor or substantially similar form), or of any employee stock option, stock purchase or compensation plan or of securities issued
or issuable pursuant to any such plan, or a dividend reinvestment plan, (ii) otherwise relating to any employee, benefit plan or corporate
reorganization or other transactions covered by Rule 145 promulgated under the Securities Act, (iii) on any registration form which does
not permit secondary sales or does not include substantially the same information as would be required to be included in a registration
statement covering the resale of the Registrable Securities. In the event the Lender desires to include in any such registration statement
all or any part of the Registrable Securities held by such Lender, the Lender shall within ten (10) days after the above-described notice
from the Company, so notify the Company in writing, including the number of such Registrable Securities such Lender wishes to include
in such registration statement. If a Lender decides not to include all of its Registrable Securities in any registration statement thereafter
filed by the Company such Lender shall nevertheless continue to have the right to include any Registrable Securities in any subsequent
registration statement or registration statements as may be filed by the Company with respect to the offering of the securities, all
upon the terms and conditions set forth herein. In the event the Company files a registration statement on Form S-1 in connection with
an uplisting of the Common shares to Nasdaq, the Effective Date shall be delayed upon mutual agreement of the Company and the Lender
in order to make any necessary amendments to the Registration Statement.

 

1.3
Obligations of the Company. Whenever required under this Section 1 to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:

 

(a)
Prepare and file with the Commission a registration statement with respect to such Registrable Securities and use its best efforts to
cause such registration statement to become effective and to keep such registration statement effective during the Effectiveness Period;

 

(b)
Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by such registration statement;

 

(c)
Furnish to the Lender, at no cost or expense to the Lender, such numbers of copies of a prospectus, including a preliminary prospectus,
in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate
the disposition of Registrable Securities owned by them (provided that the Company would not be required to print such prospectuses if
readily available to Lender from any electronic service, such as on the EDGAR filing database maintained at www.sec.gov);

 

    	 

    	 

    

 

(d)
Use its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities’
or blue sky laws of such jurisdictions as shall be reasonably requested by the Lender; provided that the Company shall not be required
in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions;

 

(e)
In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering (the Lender participating in such underwriting shall also enter into
and perform its obligations under such an agreement);

 

(f)
Promptly notify the Lender holding Registrable Securities covered by such registration statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act, within one business day, (i) of the effectiveness of such registration
statement, or (ii) of the happening of any event as a result of which the prospectus included in such registration statement, as then
in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary
to make the statements therein not misleading in the light of the circumstances then existing;

 

(g)
Cause all such Registrable Securities registered pursuant hereto to be listed on each securities exchange or nationally recognized quotation
system on which similar securities issued by the Company are then listed; and

 

(h)
Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable
Securities, in each case not later than the effective date of such registration.

 

(i)
Comply in all material respects with all applicable rules and regulations of the Commission and make generally available to its security
holders all documents filed or required to be filed with the Commission, including, but not limited, to, earning statements satisfying
the provisions of Section 11(a) of the Securities Act and Rule 158 not later than 45 days after the end of any 12-month period (or 90
days after the end of any 12-month period if such period is a fiscal year) commencing on the first day of the first fiscal quarter of
the Company after the effective date of the Registration Statement, which statement shall conform to the requirements of Rule 158.

 

(j)
If requested by the Holders of a majority in interest of the Registrable Securities, (i) promptly incorporate in a Prospectus supplement
or post-effective amendment to the Registration Statement such information as the Company reasonably agrees should be included therein
and (ii) make all required filings of such Prospectus supplement or such post-effective amendment as soon as practicable after the Company
has received notification of the matters to be incorporated in such Prospectus supplement or post-effective amendment.

 

    	 

    	 

    

 

(k)
Prior to any resale of Registrable Securities, use its commercially reasonable efforts to register or qualify or cooperate with the selling
Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable
Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder requests
in writing, to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to
do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities
covered by a Registration Statement; provided, however, that the Company shall not be required to qualify generally to do business in
any jurisdiction where it is not then so qualified or to take any action that would subject it to general service of process in any such
jurisdiction where it is not then so subject or subject the Company to any material tax in any such jurisdiction where it is not then
so subject.

 

(l)
Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be
sold pursuant to a Registration Statement, which certificates, to the extent permitted by the Purchase Agreement and applicable federal
and state securities laws, shall be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations
and registered in such names of the Holder in connection with any sale of Registrable Securities.

 

(m)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and the natural persons thereof that have voting and dispositive control over the Registrable Securities.
During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities
solely because any Holder fails to furnish such information within five (5) Business Days of the Company’s request, any liquidated
damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of
such delay shall be suspended as to such Holder only, until such information is delivered to the Company.

 

If
the Registration Statement refers to any Holder by name or otherwise as the holder of any securities of the Company, then such Holder
shall have the right to require (if such reference to such Holder by name or otherwise is not required by the Securities Act or any similar
federal statute then in force) the deletion of the reference to such Holder in any amendment or supplement to the Registration Statement
filed or prepared subsequent to the time that such reference ceases to be required.

 

Each
Holder covenants and agrees that it will not sell any Registrable Securities under the Registration Statement until the Company has electronically
filed the Prospectus as then amended or supplemented as contemplated in Section 1.3(j) and notice from the Company that the Registration
Statement and any post-effective amendments thereto have become effective as contemplated by Section 1.3(f).

 

    	 

    	 

    

 

Each
Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of
any event of the kind described in Section 1.3(f), such Holder will forthwith discontinue disposition of such Registrable Securities
under the Registration Statement until such Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration
Statement contemplated by Section 1.3(j), or until it is advised in writing (the “Advice”) by the Company that the use of
the applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are
incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement.

 

(n)
If (i) there is material non-public information regarding the Company which the Company’s Board of Directors (the “Board”)
determines not to be in the Company’s best interest to disclose and which the Company is not otherwise required to disclose, (ii)
there is a significant business opportunity (including, but not limited to, the acquisition or disposition of assets (other than in the
Common course of business) or any merger, consolidation, tender offer or other similar transaction) available to the Company which the
Board determines not to be in the Company’s best interest to disclose, or (iii) the Company is required to file a post-effective
amendment to the Registration Statement to incorporate the Company’s annual reports and audited financial statements, then the
Company may (x) postpone or suspend filing of a registration statement for a period not to exceed thirty (30) consecutive days or (y)
postpone or suspend effectiveness of a registration statement for a period not to exceed thirty (30) consecutive days; provided that
the Company may not postpone or suspend effectiveness of a registration statement under this Section 1.3(n) for more than sixty (60)
days in the aggregate during any three hundred sixty (360) day period; provided, however, that no such postponement or suspension shall
be permitted for consecutive twenty (20) day periods arising out of the same set of facts, circumstances or transactions.

 

1.4
Furnish Information. It shall be a condition precedent to the Company’s obligations to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any selling Lender that such Lender shall furnish to the Company such information
regarding such Lender, the Registrable Securities held by such Lender, and the intended method of disposition of such securities in the
form attached to this Agreement as Annex B, or as otherwise reasonably required by the managing underwriters, if any, to effect the registration
of such Lender’s Registrable Securities.

 

1.5
Delay of Registration. No Lender shall have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.

 

    	 

    	 

    

 

1.6
Indemnification.

 

(a)
To the extent permitted by law, the Company will indemnify and hold harmless the Lender, any underwriter (as defined in the Securities
Act) for such Lender and each of their directors, officers, shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person
who controls the Lender and underwriter (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act),
and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling person and their respective
heirs, personal representatives, successors and assigns, against any losses, claims, damages or liabilities (joint or several) to which
any of the foregoing persons may become subject under the Securities Act, the Exchange Act or other federal or state securities law,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof), as determined by a final judgment of a court
of competent jurisdiction from which no appeal may be taken, arise out of or are based upon any of the following statements, omissions
or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact
contained in a registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto (collectively, the “Filings”), (ii) the omission or alleged omission to state in the Filings a
material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under
the Securities Act, the Exchange Act or any state securities law, as determined by a final judgment of a court of competent jurisdiction
from which no appeal may be taken; and the Company will pay any legal or other expenses reasonably incurred by any person to be indemnified
pursuant to this Section 1.6(a) in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the indemnity agreement contained in this Section 1.6(a) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be
unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by any such Lender, underwriter or controlling person.

 

(b)
To the extent permitted by law, the Lender will indemnify and hold harmless the Company, each of its directors, each of its officers
who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act or
the Exchange Act, any underwriter, any other Lender selling securities in such registration statement and any controlling person of any
such underwriter or other Lender, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing
persons may become subject under the Securities Act, the Exchange Act or other federal or state securities law, insofar as such losses,
claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent
(and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Lender
expressly for use in connection with such registration; and each such Lender will pay any legal or other expenses reasonably incurred
by any person to be indemnified pursuant to this Section 1.6(b) in connection with investigating or defending any such loss, claim, damage,
liability or action; provided, however, that the indemnity agreement contained in this Section 1.6(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of
the Lender (which consent shall not be unreasonably withheld, conditioned or delayed); provided, however, in no event shall
any indemnity under this subsection 1.6(b) exceed the net proceeds received by such Lender upon the sale of the Registrable Securities
giving rise to such indemnification obligation.

 

    	 

    	 

    

 

(c)
Promptly after receipt by an indemnified party under this Section 1.6 of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.6,
deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate
in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the
defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together
with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party
and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within
a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve
such indemnifying party of any liability to the indemnified party under this Section 1.6, but the omission so to deliver written notice
to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section
1.6.

 

(d)
If the indemnification provided for in Sections 1.6(a) and 1.6(b) is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss,
claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand
and of the indemnified party on the other in connection with the statements or omissions or alleged statements or omissions that resulted
in such loss, liability, claim or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement
of a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. In no event shall any Lender
be required to contribute an amount in excess of the net proceeds received by such Lender upon the sale of the Registrable Securities
giving rise to such indemnification obligation.

 

(e)
If a claim for indemnification under Section 1.6(a) or 1.6(b) is due but unavailable to an Indemnified Party because of a failure or
refusal of a governmental authority to enforce such indemnification in accordance with its terms (by reason of public policy or otherwise),
then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such
Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative benefits received by the Indemnifying
Party on the one hand and the Indemnified Party on the other from the offering of the Preferred Stock and Warrants. If, but only if,
the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in
such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative
fault, as applicable, of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted
in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified
Party shall be determined by reference to, among other things, whether any action in question, including any untrue statement of a material
fact or omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified
Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement
or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set
forth in Section 1.6(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with
any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in
this Section was available to such party in accordance with its terms. In no event shall any selling Holder be required to contribute
an amount under this Section 1.6(e) in excess of the gross proceeds received by such Holder upon sale of such Holder’s Registrable
Securities pursuant to the Registration Statement giving rise to such contribution obligation.

 

    	 

    	 

    

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 1.6(e) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.

 

(f)
The obligations of the Company and Lender under this Section 1.6 shall survive the completion of any offering of Registrable Securities
in a registration statement under this Section 1, and otherwise.

 

(g)
The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may
have to the Indemnified Parties pursuant to applicable law.

 

1.7
Reports Under Securities Exchange Act. With a view to making available the benefits of certain rules and regulations of the Commission,
including Rule 144, that may at any time permit the Lender to sell securities of the Company to the public without registration or pursuant
to a registration on Form S-1 or Form S-3, the Company agrees to:

 

(a)
make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the Final Closing
Date;

 

(b)
take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to enable
the Lender to utilize Form S-1 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the
end of the fiscal year in which the registration statement is declared effective;

 

(c)
file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act; and

 

    	 

    	 

    

 

(d)
furnish to any Lender, so long as the Lender owns any Registrable Securities, forthwith upon request (i) a written statement by the Company
that it has complied with the reporting requirements of Rule 144 the Securities Act and the Exchange Act (at any time after it has become
subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-1 or
Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other
reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Lender
of any rule or regulation of the Commission that permits the selling of any such securities without registration or pursuant to such
form.

 

1.8
Transfer or Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to
this Section 1 may be transferred or assigned, but only with all related obligations, by the Lender to a transferee or assignee who (a)
acquires at least 25,000 Shares (subject to appropriate adjustment for stock splits, stock dividends and combinations) from such transferring
Lender, unless waived in writing by the Company, or (b) holds Registrable Securities immediately prior to such transfer or assignment;
provided, that in the case of (a), (i) prior to such transfer or assignment, the Company is furnished with written notice stating
the name and address of such transferee or assignee and identifying the securities with respect to which such registration rights are
being transferred or assigned, (ii) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions
of this Agreement and (iii) such transfer or assignment shall be effective only if immediately following such transfer or assignment
the further disposition of such securities by the transferee or assignee is restricted under the Securities Act.

 

1.9
Filing Obligations. The Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to Section 13(a) or 15(d) of the Exchange
Act. As long as any Holder owns Warrants or Registrable Securities, if the Company is not required to file reports pursuant to Section
13(a) or 15(d) of the Exchange Act, it will prepare and furnish to the Holders and make publicly available in accordance with Rule 144(c)
promulgated under the Securities Act, annual and quarterly financial statements, together with a discussion and analysis of such financial
statements in form and substance substantially similar to those that would otherwise be required to be included in reports required by
Section 13(a) or 15(d) of the Exchange Act, as well as any other information required thereby, in the time period that such filings would
have been required to have been made under the Exchange Act. The Company further covenants that it will take such further action as any
Holder may reasonably request, all to the extent reasonably required from time to time to enable such Person to sell the Conversion Shares
and the Warrant Shares without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated
under the Securities Act, including providing any legal opinions relating to such sale pursuant to Rule 144. Upon the request of any
Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with
such requirements.

 

    	 

    	 

    

 

	2.	Legend.

 

(a)
Each certificate representing Shares held by the Lender shall be endorsed with the following legend:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

(b)
The legend set forth above shall be removed, and the Company shall issue a certificate without such legend to the transferee of the Shares
represented thereby, if, unless otherwise required by state securities laws, (i) such Shares have been sold under an effective registration
statement under the Securities Act, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company with
an opinion of counsel, reasonably acceptable to the Company, to the effect that such sale, assignment or transfer is being made pursuant
to an exemption from the registration requirements of the Securities Act, or (iii) such holder provides the Company with reasonable assurance
that the Shares are being sold, assigned or transferred pursuant to Rule 144 or Rule 144A under the Securities Act.

 

	3.	Miscellaneous.

 

3.1
Governing Law. The parties hereby agree that any dispute which may arise between them arising out of or in connection with this
Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the State of New York and County of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of the Agreement,
then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	 

    	 

    

 

3.2
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY

 

3.3
Remedies. In the event of a breach by the Company or by a Holder of any of their obligations under this Agreement, such Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including
recovery of damages, will be entitled to specific performance of its rights under this Agreement.

 

3.4
No Inconsistent Agreements. The Company has not entered into, and shall not enter into on or after the date of this Agreement,
any agreement with respect to its securities that is inconsistent with the rights granted to the Holders in this Agreement or otherwise
conflicts with the provisions hereof. The Company has not previously entered into any agreement that is currently in effect granting
any registration rights with respect to any of its securities to any Person. Without limiting the generality of the foregoing, without
the written consent of the Holders of a majority of the then outstanding Registrable Securities, the Company shall not grant to any Person
the right to request the Company to register any securities of the Company under the Securities Act unless the rights so granted are
subject in all respects to the prior rights in full of the Holders set forth herein, and are not otherwise in conflict with the provisions
of this Agreement.

 

3.5
No Piggyback on Registrations for Other Securities. Neither the Company nor any of its security holders may include securities
of the Company in the Registration Statement, and the Company shall not after the date hereof enter into any agreement providing such
right to any of its security holders, unless the right so granted is subject in all respects to the prior rights in full of the Holders
set forth herein, and is not otherwise in conflict with the provisions of this Agreement.

 

    	 

    	 

    

 

3.6
Failure to File Registration Statement and Other Events. The Company and the Holders agree that the Holders will suffer damages
if the Registration Statement is not filed on or prior to the Filing Date and maintained in the manner contemplated herein during the
Effectiveness Period or if certain other events occur. The Company and the Holders further agree that it would not be feasible to ascertain
the extent of such damages with precision. Accordingly, if (A) the Registration Statement is not filed on or prior to the Filing Date,
or (B) the Company fails to file with the Commission a request for acceleration in accordance with Rule 461 promulgated under the Securities
Act within three (3) Business Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission
that a Registration Statement will not be “reviewed,” or not subject to further review, or (C) the Registration Statement
is filed with and declared effective by the Commission but thereafter ceases to be effective as to all Registrable Securities at any
time prior to the expiration of the Effectiveness Period, without being succeeded immediately by a subsequent Registration Statement
filed with and declared effective by the Commission in accordance with Section 1.2(a) hereof, or (F) the Company has breached Section
1.6(n) of this Agreement, or (G) trading in the Common Stock shall be suspended or if the Common Stock is no longer quoted on or is delisted
from the OTC (or other principal exchange on which the Common Stock is traded) for any reason for more than three (3) consecutive Business
Days or twelve (12) Business Days in the aggregate for any twelve month period, (any such failure or breach being referred to as an “Event,”
and for purposes of clauses (A) and (B) the date on which such Event occurs, or for purposes of clauses (C) and (F) the date on which
such three (3) Business Day period is exceeded, or for purposes of clause (D) after more than fifteen (15) Business Days, being referred
to as “Event Date”), then the Company shall pay to each Holder for liquidated damages in the amount of $250,000 and an amount
of cash each month equal to one percent (1%) of the value of the Registrable Securities held by such Holder. In addition, no liquidated
damages shall be payable with respect to Registrable Securities that may be sold pursuant to Rule 144. Notwithstanding anything to the
contrary in this paragraph (e), if (a) any of the Events described in clauses (A), (B), (C), (D) or (F) shall have occurred, (b) on or
prior to the applicable Event Date, the Company shall have exercised its rights under Section 1.6(n) hereof and (c) the postponement
or suspension permitted pursuant to such Section 3(n) shall remain effective as of such applicable Event Date, then the applicable Event
Date shall be deemed instead to occur on the second Business Day following the termination of such postponement or suspension. Liquidated
damages payable by the Company pursuant to this Section 3.6 shall be payable on the Event Date and the first (1st) Business Day of each
thirty (30) day period following the Event Date. Notwithstanding anything to the contrary contained herein, in no event shall any liquidated
damages be payable with respect to the Warrants or the Warrant Shares.

 

3.7
Waivers and Amendments. This Agreement may be terminated and any term of this Agreement may be amended or waived (either generally
or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the holders of at
least 61% of the Registrable Securities then outstanding (the “Majority Lender”). No such amendment or waiver shall
reduce the aforesaid percentage of the Registrable Securities, the holders of which are required to consent to any termination, amendment
or waiver without the consent of the record holders of all of the Registrable Securities. Any termination, amendment or waiver effected
in accordance with this Section 3.7 shall be binding upon each holder of Registrable Securities then outstanding, each future holder
of all such Registrable Securities and the Company.

 

3.8
Successors and Assigns. Except as otherwise expressly provided herein, the provisions of this Agreement shall inure to the benefit
of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. This agreement
may not be assigned without the consent of the Lender.

 

    	 

    	 

    

 

3.9
Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to
the subject matter hereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations
or covenants except as specifically set forth herein.

 

3.10
Notices. All notices and other communications required or permitted under this Agreement shall be in writing and shall be delivered
personally by hand or by overnight courier, mailed by United States first-class mail, postage prepaid, sent by facsimile or sent by electronic
mail directed (a) if to a Lender, at such Lender’s address, facsimile number or electronic mail address set forth in the Company’s
records, or at such other address, facsimile number or electronic mail address as such Lender may designate by ten (10) days’ advance
written notice to the other parties hereto or (b) if to the Company, to its address, facsimile number or electronic mail address set
forth on its signature page to this Agreement and directed to the attention of its President, or at such other address, facsimile number
or electronic mail address as the Company may designate by ten (10) days’ advance written notice to the other parties hereto. All
such notices and other communications shall be effective or deemed given upon delivery, on the date that is three (3) days following
the date of mailing, upon confirmation of facsimile transfer or upon confirmation of electronic mail delivery.

 

3.11
Interpretation. The words “include,” “includes” and “including” when used herein shall be
deemed in each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are
used for convenience only and are not considered in construing or interpreting this Agreement.

 

3.12
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall
be excluded from this Agreement, and the balance of the Agreement shall be interpreted as if such provision were so excluded, and shall
be enforceable in accordance with its terms.

 

3.13
Independent Nature of Lender’ Obligations and Rights. The obligations of the Lender hereunder are several and not joint
with the obligations of any other Lender hereunder, and no Lender shall be responsible in any way for the performance of the obligations
of any other Lender hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Lender pursuant hereto or thereto, shall be deemed to constitute the Lender as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Lender are in any way acting in concert with respect to such obligations
or the transactions contemplated by this Agreement. The Lender shall be entitled to protect and enforce its rights, including, without
limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Lender to be joined as an additional
party in any proceeding for such purpose.

 

3.14
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which
together shall constitute one instrument.

 

3.15
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

 

3.16
Shares Held by the Company and its Affiliates. Whenever the consent or approval of Holders of a specified percentage of Registrable
Securities is required hereunder, Registrable Securities held by the Company or its Affiliates (other than any Holder or transferees
or successors or assigns thereof if such Holder is deemed to be an Affiliate solely by reason of its holdings of such Registrable Securities)
shall not be counted in determining whether such consent or approval was given by the Holders of such required percentage.

 

3.17
Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more
parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic
transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall
be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute
an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, as of the date, month and year
first set forth above.

 

STEMTECH
CORPORATION

 

	 	STEMTECH
    CORPORATION
	 	 
	 	 
	 	
	 	David
    E. Price, Esq., Secretary, Corp Counsel
	 	with
    specific instructions and Authority of Charles Arnold, Dir., CEO

 

MCUS,
LLC

 

	By:	 	 
	Name:
    	 	 
	Title:	 	 

 

Address
for notice:

[  ]

[  ]

Email:

 

[SIGNATURE
PAGE TO REGISTRATION RIGHTS AGREEMENT]

 

    	 

    	 

    

 

Annex
A

 

Plan
of Distribution

 

Each
selling stockholder of the common stock and any of their pledgees, assignees and successors-in-interest may, from time to time, sell
any or all of their shares of common stock on the NASDAQ Capital Markets or any other stock exchange, market or trading facility on which
the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any
one or more of the following methods when selling shares:

 

	 	●	Common
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;
	 	 	 
	 	●	block
    trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
    principal to facilitate the transaction;
	 	 	 
	 	●	purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;
	 	 	 
	 	●	an
    exchange distribution in accordance with the rules of the applicable exchange;
	 	 	 
	 	●	privately
    negotiated transactions;
	 	 	 
	 	●	settlement
    of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
	 	 	 
	 	●	broker-dealers
    may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
	 	 	 
	 	●	through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
	 	 	 
	 	●	a
    combination of any such methods of sale; or
	 	 	 
	 	●	any
    other method permitted pursuant to applicable law.

 

The
selling stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended, if available, rather than under
this prospectus.

 

Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in
amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess
of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2440.

 

    	 

    	 

    

 

In
connection with the sale of the common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging
the positions they assume. The selling stockholders may also sell shares of the common stock short and deliver these securities to close
out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which
shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction).

 

The
selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters”
within the meaning of the Securities Act of 1933, as amended, in connection with such sales. In such event, any commissions received
by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act of 1933, as amended. Each selling stockholder has informed us that it does not have any written
or oral agreement or understanding, directly or indirectly, with any person to distribute the common stock.

 

We
are required to pay certain fees and expenses incurred by us incident to the registration of the shares. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act of 1933,
as amended.

 

Because
selling stockholders may be deemed to be “underwriters” within the meaning of the Securities Act of 1933, as amended, they
will be subject to the prospectus delivery requirements of the Securities Act of 1933, as amended, including Rule 172 thereunder. In
addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act of 1933, as
amended may be sold under Rule 144 rather than under this prospectus. There is no underwriter or coordinating broker acting in connection
with the proposed sale of the resale shares by the selling stockholders.

 

We
agreed to keep this prospectus effective until the earlier of (i) the date on which the shares may be resold by the selling stockholders
without registration and without the requirement to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144 or (ii) all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any
other rule of similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required under
applicable state securities laws. In addition, in certain states, the resale shares may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.

 

Under
applicable rules and regulations under the Securities Exchange Act of 1934, as amended, any person engaged in the distribution of the
resale shares may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted
period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject
to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, including Regulation
M, which may limit the timing of purchases and sales of shares of the common stock by the selling stockholders or any other person. We
will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this
prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act of 1933,
as amended).

 

    	 

    	 

    

 

Annex
B

 

Selling
Securityholder Notice and Questionnaire

 

The
undersigned beneficial owner of common stock (the “Registrable Securities”) of Stemtech Corporation (the “Company”),
understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”)
a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities
Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the
Registration Rights Agreement (the “Registration Rights Agreement”) to which this document is annexed. A copy of the
Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

 

Certain
legal consequences arise from being named as a selling securityholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling securityholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The
undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the
Registrable Securities owned by it in the Registration Statement.

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

1.
Name.

 

(a)
Full Legal Name of Selling Securityholder

 

(b)
Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:

 

(c)
Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to
vote or dispose of the securities covered by this Questionnaire):

 

    	 

    	 

    

 

2.
Address for Notices to Selling Securityholder:

 

Telephone:

Fax:

Contact
Person:

 

3.
Broker-Dealer Status:

 

(a)
Are you a broker-dealer?

 

Yes         No

 

(b)
If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to
the Company?

 

Yes         No

 

Note:
If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the
Registration Statement.

 

(c)
Are you an affiliate of a broker-dealer?

 

Yes         No

 

(d)
If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the Common course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly,
with any person to distribute the Registrable Securities?

 

Yes         No

 

Note:
If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the
Registration Statement.

 

4.
Beneficial Ownership of Securities of the Company Owned by the Selling Securityholder.

 

Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the securities issuable pursuant to the Purchase Agreement.

 

(a)
Type and Amount of other securities beneficially owned by the Selling Securityholder:

 

5.
Relationships with the Company:

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with
the Company (or its predecessors or affiliates) during the past three years.

 

State
any exceptions here:

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent
to the date hereof at any time while the Registration Statement remains effective.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus.

 

    	 

    	 

    

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either
in person or by its duly authorized agent.

 

Date:

 

Beneficial
Owner:

 

	By:	 	 
	Name:		 
	Title:		 

 

[SIGNATURE
PAGE FOR SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]